RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR OBTAINING THEM Russian patent published in 2014 - IPC C07K16/10 C12P21/08 A61K39/42 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of immunology and biotechnology. Presented are isolated artificial or recombinant antibody or its functional part, capable of specific binding F-antigen of respiratory-syncytial virus, which include: variable sequence of heavy chain, containing CDR1 NYIIN (SEQ ID NO:1), CDR2 GIIPVLGTVHYAPKFQG (SEQ ID NO:2), CDR3 ETALVVSTTYLPHYFDN (SEQ ID NO:3), and variable sequence of light chain, containing CDR1 QASQDIVNYLN (SEQ ID NO:4), CDR2 VASNLET (SEQ ID NO:5), CDR3 QQYDNLP (SEQ ID NO:6); as well as nucleotide sequence coding said antibody. Described is isolated mammalian cell, including said nucleic acid, where said cell expresses said nucleic sequence. Disclosed is method of obtaining antibody or its functional part, including: cultivation of said cell in vitro; and obtaining antibody or its functional fragment, produced by said cell. Described is composition for treatment or prevention of RSV-associated disorder, or preventing or counteracting unfavourable effect of RSV infection on humans, including therapeutically efficient quantity of said antibody or its functional part and pharmaceutically acceptable carrier, solvent or excipient. Claimed is application of said antibody or coding it nucleic sequence for obtaining medication for treatment or prevention of RSV-associated disorder, or preventing or counteracting unfavourable effect of RSV infection on humans.

EFFECT: invention makes it possible to extend arsenal of means for treatment or prevention of RSV-associated disorders.

22 cl, 16 dwg, 3 tbl, 5 ex